文拉法辛缓释剂与帕罗西汀治疗抑郁症对照研究

目的探讨文拉法辛缓释剂与帕罗西汀治疗抑郁症的临床疗效和安全性。方法将50例抑郁症患者随机分为两组各25例，研究组口服文拉法辛缓释剂治疗，对照组口服帕罗西汀治疗，观察6w。于治疗前及治疗第2w、4w、6w末采用汉密顿抑郁量表评定临床疗效，临床疗效总评量表-病情严重程度分量表评定疾病严重程度，副反应量表评定不良反应。结果两组治疗后汉密顿抑郁量表评分均较治疗前有显著下降（P〈0．01），且随着治疗时间的延续均呈持续性下降；研究组治疗第1w末较对照组下降更显著（P〈0．05），其他时点评分两组均无显著性差异（P〉0．05）。两组临床疗效总评量表-病情严重程度分量表治疗后评分均较治疗前有显著下降（P〈0．01），同期两组间比较均无显著性差异（P〉0．05）。两组不良反应均较轻微，多发生在治疗初期，并随着治疗的延续逐渐减轻或缓解。结论文拉法辛缓释剂与帕罗西汀治疗抑郁症效果均显著，安全性高、依从性好；但文拉法辛缓释剂起效更快，值得临床推广应用。

A controlled study of venlafaxine extended release and paroxitine in the treatment of depression

Objective To explore the clinical efficacy and safety of venlafaxine extended release （XR） and paroxetine in the treatment of depression. Methods Fifty depression patients were randomly assigned to research group（n = 25） taking orally venlafaxine XR and control group（n= 25） doing paroxetine for 6 weeks. Efficacies were assessed with Hamilton Depression Scale（HAMD）, severity of patient＇s condition with the Clinical Global Impression（CGI）, and adverse raeetions with the Treatment Emergent Symptom Scale（TESS） before treatment and at the ends of the 2nd, 4th and 6th week treatment. Results After treatment, the HAMD scores of both groups lowered more significantly compared with pretreatment（P〈 0.01） and did continously along with treatment lasting; those did more significantly in the research than in the control group at the end of the 1st week（P〈0.05）, there were no significant differences in the other time points（P〉0.05）. Severity scores of the CGI of both groups lowered more significantly after treatment compared with pretreatment（P〈0.01）, there were no singificant differences in synchronization intergroup comparisons（P〉0.05）. Adverse reactions of both groups were mild, mostly happened in the initial stage of treatment and lessened or relieved gradually along with treatment lasting. Conclusion Both venlafaxine-XR and paroxetine have notable efficacy, higher safety and better compliance in the treatment of depression; the former acts more rapidly and deserves clinical generalization and utilization.